The *Dlx5* and *Dlx6* homeobox genes are essential for craniofacial, axial, and appendicular skeletal development

Raymond F. Robledo, Lakshmi Rajan, Xue Li,¹ and Thomas Lufkin²

Brookdale Center for Developmental and Molecular Biology, Mount Sinai School of Medicine, New York, New York 10029-6574, USA

Dlx homeobox genes are mammalian homologs of the *Drosophila Distal-less (Dll)* gene. The *Dlx/Dll* gene family is of ancient origin and appears to play a role in appendage development in essentially all species in which it has been identified. In *Drosophila*, *Dll* is expressed in the distal portion of the developing appendages and is critical for the development of distal structures. In addition, human *Dlx5* and *Dlx6* homeobox genes have been identified as possible candidate genes for the autosomal dominant form of the split-hand/split-foot malformation (SHFM), a heterogeneous limb disorder characterized by missing central digits and claw-like distal extremities. Targeted inactivation of *Dlx5* and *Dlx6* genes in mice results in severe craniofacial, axial, and appendicular skeletal abnormalities, leading to perinatal lethality. For the first time, *Dlx/Dll* gene products are shown to be critical regulators of mammalian limb development, as combined loss-of-function mutations phenocopy SHFM. Furthermore, spatiotemporal-specific transgenic overexpression of *Dlx5*, in the apical ectodermal ridge of *Dlx5/6* null mice can fully rescue *Dlx/Dll* function in limb outgrowth.

[Key Words: Embryo; mouse; transgenic; knockout; cartilage; limb]

Received February 28, 2002; revised version accepted March 27, 2002.

Dlx homeobox genes are mammalian homologs of the *Drosophila Distal-less (Dll)* gene and consist of six genes that are organized into the *Dlx1/2*, *Dlx5/6*, and *Dlx3/7* bigene clusters. The vertebrate *Dlx* genes are expressed in craniofacial primordia, developing brain, and limbs, including the apical ectodermal ridge (AER). The *Dlx/Dll* gene family is of ancient evolutionary origin and has been either implicated or demonstrated to play a critical function in limb/appendage outgrowth and development in essentially all animals in which it has been identified (for review, see Panganiban 2000). In *Drosophila*, *Dll* is expressed in the distal portion of the developing appendages (limbs) and is required for proper development of distal appendage structures. Partial loss-of-function *Drosophila Dll* alleles affect primarily distal leg structures, while more severe loss-of-function *Dll* alleles extend their effects to more medial structures such as the fly tibia and femur. During development, distal cells of the fly limb retain their requirement for *Dll/Dlx* until late stages, whereas more medial cells lose this requirement earlier during fly limb outgrowth (for review, see Panganiban 2000).

Split-hand/split-foot malformation (SHFM), also referred to as ectrodactyly or lobster-claw deformity (OMIM 183600) is a human limb defect that affects growth and patterning of the central digital rays (Temtamy and McKusick 1978). The malformation is characterized by missing digits, fusion of remaining digits (syndactyly), and median clefts. SHFM is typically inherited in an autosomal dominant fashion with incomplete penetrance, variable expressivity, and segregation distortion (Scherer et al. 1994). Four human SHFM disease loci genetically map to chromosomes 7q21.3-22.1 (SHFM1, OMIM 183600), Xq26-q26.1 (SHFM2, OMIM 313350), 10q24-q25 (SHFM3, OMIM 600095), and 3q27 (SHFM4, OMIM 603237) (Faizy ul Haque et al. 1993; Scherer et al. 1994; Nunes et al. 1995; Ianakiev et al. 2000). Moreover, SHFM can present by itself or in combination with craniofacial, urogenital, ectodermal, and/or hearing abnormalities (Scherer et al. 1994; O'Quinn et al. 1998; Tackels-Horne et al. 2001).

The naturally occurring *Dactylaplasia (Dac)* mutant mouse is a phenocopy model of SHFM (Chai 1981). *Dac* maps syntenically to human chromosome 10q23-q25 and is a model for SHFM3 (Johnson et al. 1995). *Dac* embryos initiate proper limb outgrowth up to embryonic day 10.5 (E10.5). However, by E11.5 the central portion of the AER degenerates, while the anterior and posterior portions of the AER remain intact (Seto et al. 1997; Crackower et al. 1998). The AER is critical for proper

¹Present address: Howard Hughes Medical Institute and Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
²Corresponding author.

E-MAIL Thomas.Lufkin@mssm.edu; FAX 212-860-9279.

Article and publication are at <http://www.genesdev.org/cgi/doi/10.1101/gad.988402>.

limb outgrowth and patterning by signaling to the underlying progress zone and by maintaining the zone of polarizing activity (for review, see Capdevila and Izpisua Belmonte 2001). While *Dac* may be a syntenic model for only SHFM3, it can be inferred that the degeneration of the AER may be a common pathogenic feature within all forms of SHFM.

In vertebrates, the *Dlx* genes are expressed in craniofacial primordia, developing brain, and limbs, including the AER. The paired *Dlx5* and *Dlx6* genes, which map to chromosome 7q22, are postulated as candidates for SHFM1 (Scherer et al. 1994; Crackower et al. 1996). Targeted disruption or ablation of *Dlx1*, *Dlx2*, *Dlx1/2*, or *Dlx5* genes in mice results in craniofacial, bone, and vestibular defects (Qiu et al. 1997; Acampora et al. 1999; Depew et al. 1999). However, the limbs remain conspicuously absent of any abnormalities. The lack of limb defects in these mutants may be the result of genetic compensation or overlapping function with other members of the *Dlx* gene family. To explore this possibility, we performed a loss of *Dlx5* and *Dlx6* function study in mice. As hypothesized, we found that targeted disruption of both *Dlx5* and *Dlx6* results in bone, inner ear, and severe craniofacial defects. In addition, simultaneous loss of *Dlx5* and *Dlx6* gene products results in a phenocopy model of human SHFM1 and is the first demonstration of a role for mammalian *Dlx* genes in limb development.

Results

Targeted disruption of both Dlx5 and Dlx6 (Dlx5/6) in embryonic stem cells and mice

Due to their close proximity to one another on the chromosome, the *Dlx5/6* null allele was achieved by making a single deletion inactivating both genes simultaneously. As outlined in Figure 1A, *Dlx5* and *Dlx6* are arranged in a transcriptionally convergent orientation. A correctly targeted *Dlx5/6* null allele places *lacZ* under the transcriptional control of *Dlx6* 5' regulatory elements and deletes ~11 kb of DNA containing all the coding and noncoding sequence spanning the *Dlx5* and *Dlx6* homeoboxes. The absence of functional *Dlx5* or *Dlx6* homeodomains and associated C-terminal amino acids should thus result in null alleles for both *Dlx5* and *Dlx6*. Correct targeting of *Dlx5* and *Dlx6* was confirmed by Southern blot analysis employing probes internal and external to the *Dlx5/6* targeting construct (Fig. 1B). Correct *Dlx5/6* targeting was further confirmed by employing an RNA in situ hybridization probe corresponding to *Dlx6* sequences overlapping the homeobox and adjacent mRNA sequences which fall within the *Dlx5/6* null allele deleted region. In *Dlx5/6* heterozygotes, a clear signal was observed corresponding to expression in the branchial arches (ba), otic vesicle (ov), and AER from the wild-type allele. Analysis of *Dlx5/6* null embryos, however, showed no corresponding signal in the same tissues or elsewhere (Fig. 1C), indicating that deletion of this region had been successfully achieved at the *Dlx5/6* null locus.

Dlx5/6^{+/-} mutant mice were viable, fertile, and did not

have any overt physical abnormalities. In contrast, *Dlx5/6*^{-/-} mutant embryos were viable up to the time of birth, and exhibited severe limb, craniofacial, and axial skeletal defects (Fig. 1D). Obvious craniofacial defects included the complete absence of calvaria, resulting in exencephaly, reduction in the size of the eyes, and clefting and dysmorphogenesis of nasal, maxillary, and mandibular structures. Obvious axial skeletal defects included growth retardation and kinked tail vertebrae. The *Dlx5/6* null limb defects phenocopied SHFM with variable penetrance in the forelimbs and complete penetrance in the hindlimbs. The cause of death in the *Dlx5/6* nulls was likely related in part to the exencephaly, which results in cerebral trauma during fetal delivery and massive postnatal blood loss.

Dlx5/6-lacZ expression during craniofacial development

The *Dlx5/6-lacZ* expression pattern in heterozygous embryos was consistent with that previously revealed by use of RNA in situ hybridization or *lacZ* reporter expression (Simeone et al. 1994; Chen et al. 1996; Acampora et al. 1999; Depew et al. 1999). However, forebrain expression domains were reduced, likely owing to the deletion of a CNS-specific intergenic enhancer (Zerucha et al. 2000). *Dlx5/6-lacZ* expression was apparent by E8.5 in the ventral cephalic epithelium, nasal and otic placodes, and tail bud. At this stage of development, there was no apparent difference in *lacZ* expression or morphological abnormality in *Dlx5/6*^{-/-} mutant embryos (not shown). At E9.5, strong *Dlx5/6-lacZ* expression was observed in the first and second branchial arches and the otic vesicle (Fig. 2A). A phenotypic difference was first observed at E9.5, with failure of the anterior neuropore to close in *Dlx5/6*^{-/-} embryos (Fig. 2A). By E10.5, *Dlx5/6-lacZ* expression was observed in the third and fourth branchial arches and nasal placodes (Fig. 2B).

Dlx5/6-lacZ expression was strong in the epithelium of the semicircular canals and endolymphatic duct of the inner ear of *Dlx5/6*^{+/-} embryos at E11.5 (Fig. 2C). Subsequent phenotypic differences were observed in *Dlx5/6*^{-/-} embryos at E11.5 with unrecognizable inner ear structures, absence of developing eyes, dysmorphic branchial arch derivatives, and reduced *lacZ* expression in the frontonasal prominence (Fig. 2C). Severe clefting of the entire nasal cavity in *Dlx5/6*^{-/-} embryos became readily apparent by E14.5 (Fig. 2E). *Dlx5/6-lacZ* expression at this stage was severely reduced in frontonasal, maxillary, and mandibular tissues of *Dlx5/6*^{-/-} embryos. Expression in tissues giving rise to facial and calvarial structures was noticeably lost. In addition, external and middle ear expression appeared consolidated, while inner ear expression was absent.

Dlx5/6-lacZ expression during axial skeletal development

Dlx5/6-lacZ expression was observed in all sites of developing endochondral and membranous bone formation. The first abnormality in axial skeletal development

Figure 1. Simultaneous disruption of *Dlx5* and *Dlx6* by homologous recombination, genotyping, mRNA, and morphological analyses of embryos carrying a *Dlx5/6* null allele. (A) Structure of the genomic *Dlx5* and *Dlx6* loci, *ires.lacZ.neo* targeting vector, and mutant allele following homologous recombination. Exons are depicted as black boxes. The transcriptional orientation of each gene is indicated. The probes employed for Southern and RNA in situ analyses are indicated with black rectangles. (B) Southern blot analysis of embryonic genomic DNA isolated from the yolk-sac was digested with *Bam*HI and then hybridized with a 5' (probe 1) in the undelimited region of *Dlx5*, 5' (probe 2) in the undelimited region of *Dlx6*, or 3' (probe 3) in the deleted region of *Dlx5*. The wild-type and mutant alleles were detected as 6.6 kb and 2.2 kb fragments, respectively, with probe 1 and 4.3 kb and 4.6 kb, respectively, with probe 2. The wild-type allele was detected as a 6.6 kb fragment and the mutant allele was undetected with probe 3. (C) Whole-mount in situ hybridization of E10.5 wild-type and *Dlx5/6*^{-/-} embryos using probe 4. *Dlx5/6*^{-/-} embryos lack probe 4 expression as probe 4 falls

within the region deleted in the *Dlx5/6*^{-/-} embryos. (D) Gross appearance of wild-type and *Dlx5/6*^{-/-} embryos and hindlimbs at E18.5. *Dlx5/6*^{-/-} embryos show an overall reduced size, exencephaly, kinked tail vertebrae, and split hindlimbs. Scanning electron microscopy (SEM) of whole-mount wild-type and *Dlx5/6*^{-/-} embryos at E12.5, highlighting the craniofacial, tail, and limb malformations already clearly visible at this stage. Abbreviations: aer, apical ectodermal ridge; ba, branchial arches; ov, otic vesicle.

was apparent by E11.5, with the formation of a kinked tail in *Dlx5/6*^{-/-} embryos (Fig. 2C). In heterozygous em-

Figure 2. Embryonic *Dlx5* and *Dlx6* expression revealed by whole-mount β -galactosidase staining of heterozygous and homozygous *Dlx5/6* mutant embryos (Column I), with higher magnifications of limbs from the same embryos (Column II). (A) *Dlx5/6* is strongly expressed in the first and second branchial arches and the otic pit, with less prominent expression in the tail and forelimb buds at E9.5. (B) Expression becomes apparent in the AER of both fore- and hindlimb buds by E10.5. (C) At E11.5, reduction in expression in the frontonasal prominence and medial AER (arrow) initiates. (D) Expression in the medial AER deteriorates by E12.5 in *Dlx5/6*^{-/-} embryos. Arrows in the right-hand column indicate the loss of medial tissue and digits in the *Dlx5/6*^{-/-} embryos. (E) Expression within all developing bones becomes apparent by E14.5, at which time the SHFM phenotype becomes recognizable in null mutants. (F) At E18.5, craniofacial and skeletal expression remains strong. Calvarial and mandibular expression is noticeably lost in *Dlx5/6*^{-/-} embryos owing to the absence of these tissues.

bryos, *Dlx5/6-lacZ* expression in clavicles, axial skeleton, and the leading edge of calvaria was first observed at E12.5 (Fig. 2D). By E14.5, expression was observed in the perichondral region of developing long bones, ribs, and digits (Fig. 2E). The pattern of *Dlx5/6-lacZ* expression in the axial skeleton was similar between *Dlx5/6*^{+/-} and *Dlx5/6*^{-/-} embryos, suggesting that there was no significant loss of *Dlx5/6*^{-/-} cells in this domain, and furthermore, that the expression of *Dlx5/6-lacZ* was independent of any critical *Dlx5/6* cross- or autoregulatory interactions.

Dlx5/6-lacZ expression during limb development

Dlx5/6-lacZ was expressed in all developing appendages including the external ears, genital tubercle, and limb buds (Fig. 2A–F). In the developing limbs, strong expression in the AER of both the hind- and forelimb buds was observed by E10.5 and extended into the anteroproximal margins of the forelimbs by E11.5. Expression in the genital tubercle was also evident at E11.5. The first phenotypic difference in limb development was observed in the hindlimb AER of *Dlx5/6*^{-/-} embryos at E11.5. The medial portion at the AER had become thinner and the distal edge of the hindlimb had flattened. At E12.5, *Dlx5/6-lacZ* expression remained strong in the AER of *Dlx5/6*^{+/-} embryos, and digital buds were apparent. However, in *Dlx5/6*^{-/-} embryos, the medial hindlimb AER expression had degenerated, resulting in a distal flattening while still maintaining *Dlx5/6-lacZ* expression in AER lateral margins (Fig. 2D). By E14.5, *Dlx5/6-lacZ* was expressed in the epithelium and mesenchyme of digital tips and the perichondrium of the digits. In contrast, from one to three of the central hindlimb digits were absent in the hindlimbs of any given *Dlx5/6*^{-/-} embryo with normal *Dlx5/6-lacZ* expression in the remaining digits. In addition, outgrowth of the remaining digits was diverted laterally away from the midline towards the remaining distal *Dlx5/6-lacZ* expression domains persisting in the lateral edges of the AER remnant.

Cartilage and bone defects in *Dlx5/6*^{-/-} mice

Severe craniofacial cartilage defects in *Dlx5/6*^{-/-} embryos were apparent at E14.5. Exencephaly, with the absence of Alcian blue staining of frontonasal, supraoccipital, and rostral temporal areas, and the complete loss of Meckel's cartilage were the most striking defects (Fig. 3A). The inner ear capsule and middle ear cartilages were fused and severely dysmorphic, while external ear cartilage was absent. Moreover, cartilage giving rise to the cranial floor (basisoccipital, basisphenoid, and sphenoid) and frontonasal prominence were present, but with severe patterning defects. Cartilage from the exoccipital and ventral temporal bone primordia extending to the distal nasal capsule were distinctly condensed and fused. It could not be determined as to whether middle and inner ear cartilages were included within the fused structure. External ear cartilage was absent and outgrowth of the dysmorphic nasal prominence was curved caudally.

Figure 3. Craniofacial, axial, and appendicular skeletal defects of *Dlx5/6*^{-/-} embryos. (A) Whole-mount Alcian blue (AB) staining reveals the absence of Meckel's, nasal prominence and central digit cartilages of E14.5 mutant embryos. (B) Alcian blue and alizarin red (AB/AR) staining shows the absence of calvaria, maxillary, and mandibular bones of E16.5 mutant embryos. In addition, the axial skeleton, including vertebral bodies (inset), has little or no ossification and the ribs are malformed. The forelimbs (*left* columns) also have a delay in ossification (bracketed region), or a complete absence of ossification (star) and hindlimb digits (*right* columns) are absent and/or fused. (C) The delay in ossification becomes less severe in the axial and appendicular skeleton by E18.5. However, the ribs remain disfigured and the ratio of forelimb ossification to cartilage remains retarded. Hindlimbs and forelimbs (inset) have clefting due to missing and fused digits. Abbreviations: C, calvaria; FN, frontonasal cartilage; MC, Meckel's cartilage; Md, Mandible.

At E16.5, the dysmorphic cranial cartilage structure remained unossified, and maxillary and mandibular bones were absent. However, soft tissues (skin, whisker pads, tongue, and muscle) were present in a manner that defined where maxillary and mandibular structures should have developed. Endochondral ossification of the exoccipital bone primordia of *Dlx5/6*^{-/-} embryos was present at E18.5. In addition, areas of membranous ossification had developed that suggested an attempt to form maxilla, premaxilla, and nasal bones.

Defects in limb cartilage were most striking in the hindlimbs of *Dlx5/6*^{-/-} embryos. At E14.5, all combinations of the central digits were absent, similar to SHFM. Missing cartilage included phalanges, metatarsals, and tarsals (Fig. 3A–C). The most prevalent defect was the absence of the central digit. In addition, remaining adjacent digits tended to be either misshapen or fused at phalanges or metatarsals. Similar phenotypic defects were occasionally observed in the forelimbs (Fig. 3C, inset).

Endochondral bone defects were first observed at E16.5 with shorter or completely absent ossification centers in *Dlx5/6*^{-/-} embryos compared to *Dlx5/6*^{+/+} or *Dlx5/6*^{+/-} embryos (Fig. 3B). In addition, the ribs of *Dlx5/6*^{-/-} embryos were severely dysmorphic, with the greatest aberrations in the region proximal to the vertebral column. An absence or delay in endochondral ossification was observed in all bones of the appendicular and axial skeleton of *Dlx5/6*^{-/-} embryos at E16.5. By E18.5, affected endochondral ossification centers had achieved some minor developmental progression; however in all bones in the *Dlx5/6*^{-/-} embryos, the transition from a cartilaginous to ossified skeleton remained severely retarded (Fig. 3C).

Dlx5/6 can regulate endochondral ossification

Histological analysis of the delayed endochondral ossification observed in *Dlx5/6*^{-/-} embryos was performed on skeletal sections from E16.5 embryos. The scapula was

specifically chosen because the projection of the spine of scapula (Ss) can be used as an anatomical point of reference to match corresponding sections from control and *Dlx5/6* null embryos (Fig. 4A). In an area consisting of prehypertrophic, hypertrophic, and calcified (von Kossa-positive) chondrocytes in *Dlx5/6*^{+/-} sections, comparable *Dlx5/6*^{-/-} sections were composed of only prehypertrophic chondrocytes (Fig. 4B), indicating a retardation of the normal chondrocyte developmental program. In progressive serial sections, *Dlx5/6*^{+/-} skeletal sections showed

the presence of vascularization and a mineralized bone matrix. In contrast, comparable regions in *Dlx5/6*^{-/-} embryos consisted of hypertrophic and calcified chondrocytes, minimal vascular invasion, and a predominantly cartilage matrix (Fig. 4B).

Molecular analysis of comparable E16.5 *Dlx5/6*^{-/-} embryos also suggested a delay in the onset of the osteogenic pathway. Relative to wild-type embryos, *Dlx5/6*^{-/-} embryos showed normal expression of *Sox9*, a regulator of precartilaginous condensation (data not shown). In

contrast, *Col2a1* and *Col10a1* expression, indicators of prehypertrophic and hypertrophic chondrocytes, were still actively transcribed in *Dlx5/6*^{-/-} sections, whereas in the same skeletal region in *Dlx5/6*^{+/-} embryos, both genes had already been significantly downregulated (Fig. 4C). *Fgf-Fgfr3* and *Ihh-Pthrp-Pthrp-r* signaling pathways are known to be important regulators of chondrocyte proliferation and differentiation that couples chondrogenesis to osteogenesis during endochondral ossification (Naski et al. 1998; Chung et al. 2001). Similar to what was observed for *Col2a1* and *Col10a1*, there was a temporal delay in *Fgfr3* and *Ihh* expression in the *Dlx5/6*^{-/-} scapula (data not shown; Fig. 4C) such that comparable regions between control and *Dlx5/6*^{-/-} null embryos showed opposing patterns of *Fgfr3* and *Ihh* expression. Interestingly, *Pthrp-r* expression was unaffected in the *Dlx5/6*^{-/-} null embryos (Fig. 4C).

The *Runx2* (*Osf2/Cbfa1*) transcription factor has been shown to be a regulator of chondrocyte and osteoblast differentiation and a direct inducer of osteoblast-specific *Osteocalcin* expression (Ducy et al. 1997; Takeda et al. 2001). Similar *Runx2* expression patterns were observed within the chondrium and perichondrium of comparable *Dlx5/6*^{+/-} and *Dlx5/6*^{-/-} skeletal sections (Fig. 4C). However, there appears to be a decrease in the number of cells expressing *Runx2* within the chondrium. In contrast, *Osteocalcin* gene expression was dramatically absent in *Dlx5/6*^{-/-} skeletal sections (Fig. 4A,C), suggesting that *Dlx5/6* have a critical positive role in the osteoblast maturation pathway, and in their absence, the accumulation of mature osteoblasts is severely retarded or absent.

Dlx5/6 are essential for hindlimb AER maintenance

The earliest morphological limb abnormalities in *Dlx5/6*^{-/-} embryos were observed at E11.5 (Fig. 2C). Therefore, molecular analysis of genes known to regulate limb development (for review, see Capdevila and Izpisua Belmonte 2001) was performed at this and earlier stages. *Shh* expression in the zone of polarizing activity has been shown to be a critical mediator of anterior-posterior limb patterning. Its expression was identical between wild-type and *Dlx5/6*^{-/-} embryos at E10.5 and E11.5 (Fig. 5). Similarly, there were no alterations in the expression pattern of *Lmx1b*, a regulator of limb dorsal-ventral patterning (Fig. 5). *Fgf8* expression in the AER, which is required for proximal-distal patterning and outgrowth, was normal for *Dlx5/6*^{-/-} embryos at E10.5 (Fig. 5). However, *Fgf8* expression in *Dlx5/6*^{-/-} embryos was lost in the medial portion of the hindlimb AER by E11.5 (Fig. 5). Furthermore, *Msx2* expression in the hindlimb AER and progress zone (PZ) of *Dlx5/6*^{-/-} embryos was normal at E10.5 and by E11.5 was clearly absent in the medial AER and underlying PZ (Fig. 5). *Dlx2*, another member of the mammalian *Dlx* family, which shows strong similarity to *Dlx5* and *Dlx6* in expression and sequence, is coexpressed with *Dlx5* and *Dlx6* in the AER. No alterations of *Dlx2* expression were observed prior to E11.5, suggesting that there were no critical cross-regulatory interac-

tions between *Dlx5/6* and *Dlx2*. At E11.5, expression of *Dlx2* like that of the other AER markers, was missing from the medial region of the distal limb (Fig. 5). To follow the specific fate of cells normally expressing *Dlx5* and *Dlx6*, we used a probe corresponding to the 5' end of *Dlx5*, which is still present in the *Dlx5/6* null mutation and should thus be transcribed. The expression of the *Dlx5* 5' probe paralleled what was observed for other markers of the AER, namely normal expression was observed prior to E11.5, but following this stage there was a progressive loss of expression from the distal medial region of the limb. As normal levels and spatiotemporal expression of *Dlx5* 5' was observed in the *Dlx5/6*^{-/-} embryos, we can conclude that neither the position nor the migration of *Dlx5/6* null cells was severely affected in the limbs of *Dlx5/6*^{-/-} embryos prior to E11.5. *Dss1* (*deleted in split-hand/split-foot 1*) is a gene encoding a unique protein located near *Dlx5* and *Dlx6* on the chromosome and is also expressed in the developing distal limb, including the AER (Crackower et al. 1996). Owing to its proximity to the SHFM1 critical region and its expression in the developing limb, *Dss1* has been considered a candidate gene for SHFM1. Interestingly, no alteration of *Dss1* expression in the developing limb of the *Dlx5/6*^{-/-} embryos was observed prior to E11.5. From this stage on, *Dss1* expression, like all other markers for the distal limb, was decreasing or missing from the distal medial portion of the *Dlx5/6*^{-/-} limb (not shown).

Morphological and molecular examination of the *Dlx5/6*^{-/-} limbs suggested a progressive loss of distal medial limb cells with an onset immediately prior to E11.5. Possible explanations for cell loss are a decreased rate of cell proliferation or an increase in the number of cells locally undergoing programmed cell death. Programmed cell death in the AER and underlying mesenchyme was therefore measured by analyzing DNA fragmentation with a TUNEL assay; however, no significant difference was observed between wild-type and *Dlx5/6*^{-/-} embryos in either of these cell types (not shown), suggesting that the loss of limb tissue observed in the *Dlx5/6*^{-/-} embryos was unrelated to the specific cell death-mediated elimination of *Dlx5/6*^{-/-} cells. In contrast, BrdU incorporation to mark cycling cells indicated a significant decrease in the number of proliferating cells within the hindlimb AER of *Dlx5/6*^{-/-} embryos at both E10.5 and E11.5 (Fig. 5). However, cell proliferation in the underlying mesenchyme was normal at both stages for null embryos. These data indicate that a principal role for *Dlx5/6* is maintenance of normal proliferation rates within the cells of the medial AER at E10.5 and E11.5. Loss of *Dlx5/6* resulted in a localized decrease in cell proliferation within the medial AER and subsequent loss of limb structures (medial digits) arising from the underlying mesenchyme, which is regulated by the overlying AER.

Msx2 AER-specific transgene-driven Dlx5 expression rescues SHFM in Dlx5/6^{-/-} mice

Transgenic mice were generated that overexpress *Dlx5* in the AER under the control of the *Msx2* AER-specific

enhancer (Fig. 6A; Liu et al. 1994). The transgenic mice have no conspicuous phenotypic abnormalities even though transgene-specific expression by RNA in situ hybridization or of a coinjected *alkaline phosphatase* reporter confirmed that the *AER-Dlx5* transgene was being expressed in the AER (Fig. 6B). Transgenic mice were subsequently bred onto the *Dlx5/6* mutant background to determine whether AER-specific *Dlx5* overexpression could rescue the SHFM defect in *Dlx5/6*^{-/-} embryos. *AER-Dlx5* transgenic *Dlx5/6*^{-/-} embryos were stillborn and presented craniofacial and vertebral defects identical to those described for nontransgenic *Dlx5/6*^{-/-} embryos. In addition, *AER-Dlx5* expression was capable of fully rescuing the SHFM phenotype (Fig. 6C). Cartilage staining of E14.5 embryos showed normal hindlimb structures in both *Dlx5/6*^{+/+}; *AER-Dlx5*⁺ and *Dlx5/6*^{-/-}; *AER-Dlx5*⁺ mice (Fig. 6C). Proximal-distal outgrowth, patterning, and ossification within developing hindlimbs also proceeded in a normal manner (Fig. 6C). Further-

more, molecular analysis revealed that *Fgf8* and *Msx2* were expressed in the hindlimbs of *Dlx5/6*^{-/-}; *AER-Dlx5*⁺ mice at E12.5 (Fig. 6C). As described above, *Fgf8* and *Msx2* expression were lost in the central hindlimb AER from E11.5 onward in the *Dlx5/6* null embryos (Fig. 5).

Discussion

Role of *Dlx5/6* in control of craniofacial development

Dlx5/6^{-/-} mice have a multitude of craniofacial and ear defects including the failure of Meckel's cartilage, mandible, and calvaria formation. The craniofacial and ear defects reported here are dramatically more severe than those observed in *Dlx5*-deficient mice (Acampora et al. 1999; Depew et al. 1999), which suggests that *Dlx5* and *Dlx6* have unique and redundant functions. Numerous genes are required for proper ear and craniofacial development, including *Prx1*, *Prx2*, *Msx1*, *Msx2*, *Endothelin-1*

Figure 6. SHFM phenotypic rescue of *Dlx5/6*^{-/-} embryos by *Dlx5* transgene expression in the developing AER. (A) Structure of the *Dlx5* and *alkaline phosphatase* (AP) transgenes that employ the *Msx2* AER-specific enhancer. (B) Whole-mount in situ hybridization of *AER-Dlx5/AP* embryos showing AER expression of the tagged (TAG) *Dlx5* transgene and transgene-specific alkaline phosphatase staining of the AER at E10.5. (C) AB staining at E14.5 shows restored hindlimb cartilage outgrowth and patterning of *Dlx5/6*^{-/-} embryos expressing the *AER-Dlx5/AP* transgene. AB/AR cartilage and bone staining of the hindlimbs remains rescued at E18.5. Whole-mount in situ hybridization at E12.5 shows that AER expression of both *Fgf8* and *Msx2* can be restored by *AER-Dlx5/AP* expression in mutant mice. Arrowheads at E12.5 indicate the loss of marker expression and missing tissue in the medial portion of the distal limb in the *Dlx5/6*^{-/-} embryos lacking the *AER-Dlx5/AP* transgene.

(*Edn1*), and *Endothelin-A receptor* (*ET_A*). Mice null for *Prx1/2*, *Msx2*, *Edn1*, or *ET_A* have craniofacial and ear defects that have some similarity to a portion of the defects in *Dlx5/6*^{-/-} mice (ten Berge et al. 1998; Thomas et al. 1998; Clouthier et al. 2000; Satokata et al. 2000). However, the defects in all of the aforementioned studies are to a lesser extent and severity. Furthermore, recent observations suggest that *Dlx6* and not *Dlx5* acts as a transducer of *Edn1*-dependent expression of *dHAND* in the first branchial arch of mice (Charite et al. 2001). The mechanisms by which *Dlx5* and *Dlx6* regulate craniofacial and ear development are obviously complex and are

the focus of ongoing studies. We propose that they function directly and indirectly as global coordinators of a number of signaling pathways that are critical for craniofacial development.

Role of *Dlx5/6* in control of endochondral ossification

Dlx5 and *Dlx6* are essential regulators of endochondral ossification, as *Dlx5/6*^{-/-} mice have normal early cartilage formation of long bones at E14.5, but axial and appendicular skeleton show severe retardation in chondrocyte/cartilage and osteoblast differentiation and sub-

sequent mineralization. Prechondrocyte condensation appears unaffected in mutant mice, as *Sox9* expression patterns and levels are normal. The requirement for *Dlx5/6* appears during the transition from prehypertrophic to hypertrophic chondrocytes. The onset of *Col2a1* expression is normal in the *Dlx5/6*^{-/-} embryos, but the differentiation to *Col10a1*- and *Runx2*-expressing cells in the chondrium is either blocked or severely retarded. In addition, the gene expression patterns for *Fgf-Fgfr3* and *Ihh-Pthrp-Pthrp-r* signaling pathways, key regulators of chondrogenesis, are likewise blocked or severely retarded. Disruption of these pathways can result in a delay in osteogenesis that is secondary to cartilage maturation, as *Ihh* has recently been shown to couple the transition from chondrogenesis to osteogenesis (Chung et al. 2001).

Dlx5 and *Dlx6* could also be direct regulators of osteogenesis or osteoblast differentiation. *Dlx5*-deficient mice exhibit a mild delay in ossification of long bones, without effecting *Runx2* expression (Acampora et al. 1999). It has been proposed that *Dlx5* may be a downstream target of *Runx2* or act independently, but in a similar role. *Dlx5* and *Dlx6* do not appear to be direct targets of *Runx2*, because *Runx2*-deficient mice almost completely fail to form bone (Komori et al. 1997; Otto et al. 1997). They do appear to act independently in the activation of *Osteocalcin*, as *Osteocalcin* expression is absent in skeletal sections of *Dlx5/6*^{-/-} mice, while perichondral *Runx2* expression is normal in adjacent sections. However, the present data suggest that *Dlx5* and *Dlx6* regulate cartilage maturation, which in turn regulates the onset of osteogenesis.

In vitro overexpression of *Dlx5* can induce *Osteocalcin* production in murine osteoblasts (Miyama et al. 1999). Furthermore, there is increasing evidence that *Dlx5* promotes activation of *Osteocalcin* by forming heterodimers with *Msx2*, which antagonizes the *Msx2*-mediated repression of *Osteocalcin* (Newberry et al. 1998; Shirakabe et al. 2001). Overexpression of *Msx2* prevents osteoblast differentiation, whereas inhibition of *Msx2* translation accelerates differentiation (Dodig et al. 1999; Liu et al. 1999). In addition, *Msx2*-deficient mice have alterations in both chondrogenesis and osteogenesis that cause defective endochondral bone formation (Satokata et al. 2000). Therefore, delayed endochondral ossification in *Dlx5/6*^{-/-} mice could be the result of increased *Msx2* activity, in the absence of altered *Msx2* or *Runx2* gene expression. Another possibility is that *Dlx5/6* act along parallel pathways for the promotion and linkage of chondrocyte and osteoblast maturation. *Dlx5/6* could possibly act as potentiators of *Sox5* and *Sox6* function. *Sox5* and *Sox6* are possible downstream targets of *Sox9* and are essential for the transition from prehypertrophic to hypertrophic chondrocytes (Smits et al. 2001). This could be the basis for the reduced number of *Runx2*-expressing hypertrophic chondrocytes within the chondrium of *Dlx5/6* null embryos. A reduction in the number of *Runx2*-expressing chondrocytes could subsequently result in a retardation of bone formation, as *Runx2* is critical for hypertrophic differentiation and vascular invasion

(Zelzer et al. 2001). This assumes that the total number or concentration of *Runx2*-expressing cells is critical. Alternately, *Dlx5/6* could promote the differentiation of a mesenchymal progenitor to a mature osteoblast within the perichondrium. Perichondrial *Runx2* expression or other factors might partially compensate for the loss of *Dlx5/6*; however, the compensation is incomplete and results in delayed endochondral ossification and stunted bone growth.

Role of Dlx5/6 in control of limb development

Dlx5/6 control proximal-distal patterning in the murine hindlimb by maintaining the medial portion of the AER. Degeneration of the AER in *Dlx5/6*^{-/-} mice results in a phenocopy of SHFM1. The SHFM in *Dlx5/6* null mice has similarities to the *Dac* mouse model of SHFM3; however, in *Dac* mice, the AER degenerates owing to aberrant cell death within the AER (Seto et al. 1997; Crackower et al. 1998). In *Dlx5/6*^{-/-} embryos, no alterations in cell death were observed in the AER or adjacent mesenchyme. In the *Dlx5/6*^{-/-} embryos, expression of *Fgf8* and *Msx2* was lost in the medial portion of the AER by E11.5, while *Dlx5/6-lacZ* was still being expressed. Since *Dlx5/6* are normally expressed in the AER with expansion into the PZ by E12.5, they appear to be essential for the survival of at least one cell population in the AER. Observations from analyses of *Dac* mice have implicated *Fgf8* as a regulator of AER maintenance and the cause of SHFM. The present results rule out *Fgf8* as the cause of *Dlx5/6*-mediated SHFM because *Dlx5/6*^{-/-} mice have decreased cell proliferation in the AER by E10.5 at a time when *Fgf8* expression is normal. In addition, conditional loss of *Fgf8* expression in the mouse limb bud does not result in any form of SHFM (Lewandoski et al. 2000; Moon and Capecchi 2000). In fact, the limb defects reported in conditional *Fgf8* null mice are less severe than those observed in the *Dlx5/6* null embryos.

Dlx5 and *Dlx6* show redundant control of AER maintenance, as mice lacking *Dlx5* alone have no obvious limb defects (Acampora et al. 1999; Depew et al. 1999), and overexpression of *Dlx5* in the AER of *Dlx5/6*^{-/-} mice rescues the SHFM in the absence of any *Dlx6* expression. The targets of *Dlx5* and/or *Dlx6* protein function appear to be at maximal levels in wild-type mice, as overexpression of *Dlx5* on a wild-type genetic background has no effect on limb development. One possible model consistent with these results would have wild-type *Dlx5* and *Dlx6* functioning as transcriptional repressors of an overlapping set of downstream target genes. When the levels of *Dlx5*- and *Dlx6*-mediated repression fall below a critical threshold owing to loss of *Dlx5* and *Dlx6* alleles, certain genes within the AER may become active and affect either directly or indirectly the proliferation of cells within the AER. On a wild-type background, the overexpression of *Dlx5* via an introduced transgene may have no effect, as the normal targets of *Dlx5* and *Dlx6* are already fully repressed. Naturally, converse models with *Dlx5* and *Dlx6* functioning as "activators" of a repressor would also be consistent with the observed results.

In humans, SHFM can be inherited in a regular dominant manner over multiple generations, yet also show lack of penetrance with skipped generations or irregular 'dominant' inheritance. In mice, the loss of a single *Dlx5/6* locus (gene pair) is fully recessive with regards to the SHFM phenotype. These results might indicate that the human genome contains certain combinations of genetic modifiers which make limb development more sensitive to reduced levels of *Dlx5/6* protein or possibly that certain types of SHFM mutations in human function in a dominant-negative manner, possibly by negatively interfering with the normal function of a shared cofactor.

In conclusion, *Dlx5* and *Dlx6* are dynamic regulators of mammalian development, which are absolutely required for proper craniofacial and skeletal development and which display overlapping genetic functions in all tissues in which they are expressed. In addition, they appear to act as essential regulators of chondrogenesis and osteogenesis. Finally, they are essential for maintenance of the medial portion of the hindlimb AER, as their loss leads to AER degeneration that results in a phenocopy of SHFM1 with craniofacial defects. These results are also the first example of an evolutionary conserved role for mammalian *Dlx* genes in limb outgrowth and development, a function the *Dlx/Dll* gene family appears to share among all species with appendages.

Materials and methods

Generation of *Dlx5/6* null mutant and AER-*Dlx5* transgenic mice

Three overlapping lambda clones containing *Dlx5* and *Dlx6* from a 129/Sv genomic library were obtained following a low-stringency screen performed as described (Chen et al. 1996). The inserts from the phage were subcloned into plasmid pTZ18 for restriction mapping and DNA sequencing, which confirmed that they contained the genes for *Dlx5* and *Dlx6*. An artificial *NruI* site was subsequently introduced into the homeobox sequence of *Dlx6* by site-directed mutagenesis. The *Dlx5/6* targeting construct pSL99 was generated using a 12-kb *BglIII-NruI* homology arm spanning the 5' end of the *Dlx6* gene up to the artificial *NruI* site in the *Dlx6* homeobox. The second homology arm of the targeting construct corresponded to a 1.5 kb *SalI-BglIII* genomic fragment overlapping the 5' end of *Dlx5* and containing exon I (exon II and exon III encode the homeodomain). The *ires-lacZ-neo* cassette (Wang et al. 2001) was inserted with the *ires* sequence abutting the *Dlx6* homeobox sequence; thus, a correctly targeted clone would lack a functional *Dlx5* and *Dlx6* homeodomain and associated C-terminal amino acids, which should result in null alleles for both genes. The *ires-lacZ* sequences therefore fall under the control of the *Dlx6* 5' transcriptional regulatory regions, and any regulatory sequences that lay between *Dlx5* and *Dlx6* would thus be removed. ES cell electroporation, selection, Southern blotting, chimera production, and testing were performed essentially as described (Wang et al. 2001).

The AER-specific transgenes were constructed using the *Msx2* AER-specific enhancer/promoter (Liu et al. 1994) kindly provided by Robert Maxson (University of Southern California Medical School, Los Angeles). To generate the AER-*Dlx5* trans-

gene, the 0.5 kb *Msx2* AER-specific enhancer/promoter fragment was ligated to the 0.9 kb *Dlx5* ORF (kindly provided by Cory Abate-Shen, UMDNJ, Piscataway, NJ), followed by a 0.96 kb *BglIII-NotI* fragment derived from the 3' untranslated region of *Drosophila Hmx* (*DHmx*) cDNA (Wang et al. 2000) inserted in the inverted orientation, which serves as a noncoding transgene-specific "tag" sequence employed specifically for RNA in situ hybridization purposes. Finally, a 0.25 kb SV40-derived polyadenylation sequence was ligated to the 3' end (Frasch et al. 1995). To generate the AER-AP transgene, the above-mentioned *Msx2* AER-specific fragment was ligated to the *ires-alkaline phosphatase* reporter gene (Li et al. 1997), which places the *alkaline phosphatase* cDNA under the control of the *Msx2* AER-specific enhancer/promoter sequences. The above-mentioned 0.25 kb SV40-derived polyadenylation sequence was ligated to the 3' end as well. Both transgenes were gel purified, mixed in equal molar ratios, and microinjected into 1-cell mouse embryos as described (Frasch et al. 1995). Southern blotting of tail tip DNA identified ten stable transgenic founder lines carrying either one or both transgene constructs. Transgenic lines having cointegrated both transgenes were identified by continual cosegregation of the two transgene alleles after several sequential generations of outbreeding (transgenic X wild-type) and were employed for further analysis.

Embryos ranging in age from E8.5 to 18.5 were collected for whole-mount β -galactosidase staining, as described (Wang et al. 2001). Noon of the vaginal plug date was designated as E0.5. AER-*Dlx5*/AER-AP transgenic embryos, ranging in age from E8.5 to E14.5, were collected for whole-mount alkaline phosphatase staining (Li et al. 1997) and RNA in situ hybridization (Wang et al. 2001) as described.

Skeletal, histological, and RNA in situ analyses

Whole-mount cartilage and ossified skeletal elements were analyzed by staining collected embryos with Alcian blue or combined Alcian blue/alizarin red. For cartilage staining, E12.5 to E14.5 embryos were fixed overnight in Bouin's solution, stained in Alcian blue, and cleared as described (Tribioli and Lufkin 1999). For combined cartilage/bone analysis, E15.5 to E18.5 embryos were collected, and skin and internal organs were removed and fixed overnight in 95% ethanol. Skeletal preparations were then stained with Alcian blue followed by alizarin red staining and then cleared, as described (Tribioli and Lufkin 1999).

For histological analysis of scapulas, embryos were collected at E16.5 and the forelimbs were isolated, oriented, and embedded in paraffin for serial transverse sectioning (7 μ m) using standard histological techniques. The spine of scapula (Ss) was used as an anatomical landmark to match control and mutant sections for staining or RNA in situ hybridization (described below). Matched scapula sections were stained with Alcian blue or von Kossa's techniques as described (Sheehan and Hrapchak 1987; Tribioli and Lufkin 1999).

In situ hybridization experiments on transverse paraffin embedded scapula sections (described above) were performed as described (Wang et al. 2001). The following cDNAs were used to synthesize antisense [35 S]UTP-RNA probes: 500 bp *Col2a1*, 500 bp *Col10a1*, 270 bp *Runx2*, 470 bp *Osteocalcin*, 400 bp *Fgfr3*, 1800 bp *Ihh*, 500 bp *Pthrp-r*, and 500 bp *Sox9*. Nonradioactive whole-mount in situ hybridization experiments were performed on embryos collected between E9.5 and E14.5, as described (Wang et al. 2001). The following cDNAs were used to synthesize antisense digoxigenin-11-UTP-RNA probes: 400 bp *Fgf8*, 1300 bp *Lmx1b*, 1000 bp *Msx2*, 960 bp *DHmx*, 330 bp *Dlx5* 5', 560 bp *Dlx2*, and 2600 bp *Shh*.

Cell proliferation and apoptosis

Cell proliferation was determined by measuring the incorporation of 5-bromo-2'-deoxyuridine (BrdU) into the cells of E10.5 to E13.5 embryos. Embryos were collected from pregnant mice one hour following a 50 µg/g intraperitoneal BrdU injection and processed as described (Tribioli and Lufkin 1999; Wang et al. 2001). Apoptotic cell death was determined by measuring cells containing fragmented DNA utilizing the ApopTag kit (Intergen), as described (Ahuja et al. 1997). Briefly, tissue sections were postfixed with ethanol:acetic acid (2:1) followed by quenching of endogenous peroxidases with 3% hydrogen peroxide. Sections were then treated with digoxigenin-11-dUTP in the presence of terminal transferase for 90 min at 37°C. The digoxigenin-11-dUTP reaction to the free end of DNA was detected by using diaminobenzidine as substrate for a peroxidase conjugated antidigoxigenin antibody. At least three embryos for each genotype at each embryonic stage were examined for either cell proliferation or apoptosis.

Acknowledgments

We thank Robert Maxson for the *Msx2* AER-specific enhancer, Cory Abate-Shen for the *Dlx5* ORF cDNA, Edoardo Boncinelli, Mitch Goldfarb, Jill Helms, Randy Johnson, Gerard Karsenty, Peter Koopman, Gail Martin, Andy McMahon, Shintaro Nomura, Bjorn Olsen, Francesco Ramirez, John Rubenstein, David Sassoon, and Motohiko Sato for providing RNA in situ probes. The NIH (AR43449, DE013076, and DE013741) has supported different parts of this work.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

- Acampora, D., Merlo, G.R., Paleari, L., Zerega, B., Postiglione, M.P., Mantero, S., Bober, E., Barbieri, O., Simeone, A., and G. Levi. 1999. Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene *Dlx5*. *Development* **126**: 3795–3809.
- Ahuja, H.S., Zhu, Y., and Zakeri, Z. 1997. Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. *Dev Genet* **21**: 258–267.
- Capdevila, J. and Izpisua Belmonte, J.C. 2001. Patterning mechanisms controlling vertebrate limb development. *Annu Rev Cell Dev Biol* **17**: 87–132.
- Chai, C.K. 1981. Dactylaplasia in mice a two-locus model for development anomalies. *J Hered* **72**: 234–237.
- Charite, J., McFadden, D.G., Merlo, G., Levi, G., Clouthier, D.E., Yanagisawa, M., Richardson, J.A., and Olson, E.N. 2001. Role of *Dlx6* in regulation of an endothelin-1-dependent, dHAND branchial arch enhancer. *Genes Dev* **15**: 3039–3049.
- Chen, X., Li, X., Wang, W., and Lufkin, T. 1996. *Dlx5* and *Dlx6*: An evolutionary conserved pair of murine homeobox genes expressed in the embryonic skeleton. *Ann N Y Acad Sci* **785**: 38–47.
- Chung, U.I., Schipani, E., McMahon, A.P., and Kronenberg, H.M. 2001. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. *J Clin Invest* **107**: 295–304.
- Clouthier, D.E., Williams, S.C., Yanagisawa, H., Wieduwilt, M., Richardson, J.A., and Yanagisawa, M. 2000. Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. *Dev Biol* **217**: 10–24.
- Crackower, M.A., Motoyama, J., and Tsui, L.C. 1998. Defect in the maintenance of the apical ectodermal ridge in the Dactylaplasia mouse. *Dev Biol* **201**: 78–89.
- Crackower, M.A., Scherer, S.W., Rommens, J.M., Hui, C.C., Poorkaj, P., Soder, S., Cobben, J.M., Hudgins, L., Evans, J.P., and Tsui, L.C. 1996. Characterization of the split hand/split foot malformation locus SHFM1 at 7q21.3-q22.1 and analysis of a candidate gene for its expression during limb development. *Hum Mol Gen* **5**: 571–579.
- Depew, M.J., Liu, J.K., Long, J.E., Presley, J.E., Meneses, J.J., Pedersen, R.A., and Rubenstein, J.L. 1999. *Dlx5* regulates regional development of the branchial arches and sensory capsules. *Development* **126**: 3831–3846.
- Dodig, M., Tadic, T., Kronenberg, M.S., Dacic, S., Liu, Y.H., Maxson, R., Rowe, D.W., and Lichtler, A.C. 1999. Ectopic *Msx2* overexpression inhibits and *Msx2* antisense stimulates calvarial osteoblast differentiation. *Dev Biol* **209**: 298–307.
- Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L., and Karsenty, G. 1997. *Osf2/Cbfa1*: A transcriptional activator of osteoblast differentiation. *Cell* **89**: 747–754.
- Faiyaz ul Haque, M., Uhlhaas, S., Knapp, M., Schuler, H., Friedl, W., Ahmad, M., and Propping, P. 1993. Mapping of the gene for X-chromosomal split-hand/split-foot anomaly to Xq26-q26.1. *Hum Genet* **91**: 17–19.
- Frasch, M., Chen, X., and Lufkin, T. 1995. Evolutionary-conserved enhancers direct region-specific expression of the murine *Hoxa-1* and *Hoxa-2* loci in both mice and *Drosophila*. *Development* **121**: 957–974.
- Ianakev, P., Kilpatrick, M.W., Toudjarska, I., Basel, D., Beighton, P., and Tsipouras, P. 2000. Split-hand/split-foot malformation is caused by mutations in the *p63* gene on 3q27. *Am J Hum Genet* **67**: 59–66.
- Johnson, K.R., Lane, P.W., Ward-Bailey, P., and Davisson, M.T. 1995. Mapping the mouse dactylaplasia mutation, *Dac*, and a gene that controls its expression, *mdac*. *Genomics* **29**: 457–464.
- Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al. 1997. Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* **89**: 755–764.
- Lewandoski, M., Sun, X., and Martin, G.R. 2000. *Fgf8* signalling from the AER is essential for normal limb development. *Nat Genet* **26**: 460–463.
- Li, X., Wang, W., and Lufkin, T. 1997. Dicistronic LacZ and alkaline phosphatase reporter constructs permit simultaneous histological analysis of expression from multiple transgenes. *Biotechniques* **23**: 874–878.
- Liu, Y.H., Ma, L., Wu, L.Y., Luo, W., Kundu, R., Sangiorgi, F., Snead, M.L., and Maxson, R. 1994. Regulation of the *Msx2* homeobox gene during mouse embryogenesis: A transgene with 439 bp of 5' flanking sequence is expressed exclusively in the apical ectodermal ridge of the developing limb. *Mech Dev* **48**: 187–197.
- Liu, Y.H., Tang, Z., Kundu, R.K., Wu, L., Luo, W., Zhu, D., Sangiorgi, F., Snead, M.L., and Maxson, R.E. 1999. *Msx2* gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: A possible mechanism for *MSX2*-mediated craniosynostosis in humans. *Dev Biol* **205**: 260–274.
- Miyama, K., Yamada, G., Yamamoto, T.S., Takagi, C., Miyado, K., Sakai, N., Ueno, M., and Shibuya, H. 1999. A BMP-inducible gene, *dlx5*, regulates osteoblast differentiation and mesoderm induction. *Dev Biol* **208**: 123–133.

- Moon, A.M. and Capecchi, M.R. 2000. Fgf8 is required for outgrowth and patterning of the limbs. *Nat Genet* **26**: 455–459.
- Naski, M.C., Colvin, J.S., Coffin, J.D., and Ornitz, D.M. 1998. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. *Development* **125**: 4977–4988.
- Newberry, E.P., Latifi, T., and Towler, D.A. 1998. Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. *Biochemistry* **37**: 16360–16368.
- Nunes, M.E., Schutt, G., Kapur, R.P., Luthardt, F., Kukolich, M., Byers, P., and Evans, J.P. 1995. A second autosomal split hand/split foot locus maps to chromosome 10q24-q25. *Hum Mol Genet* **4**: 2165–2170.
- O'Quinn, J.R., Hennekam, R.C., Jorde, L.B., and Bamshad, M. 1998. Syndromic ectrodactyly with severe limb, ectodermal, urogenital, and palatal defects maps to chromosome 19. *Am J Hum Genet* **62**: 130–135.
- Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen, B.R. et al. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* **89**: 765–771.
- Panganiban, G. 2000. Distal-less function during Drosophila appendage and sense organ development. *Dev Dyn* **218**: 554–562.
- Qiu, M., Bulfone, A., Ghattas, I., Meneses, J.J., Christensen, L., Sharpe, P.T., Presley, R., Pedersen, R.A., and Rubenstein, J.L. 1997. Role of the Dlx homeobox genes in proximodistal patterning of the branchial arches: Mutations of Dlx-1, Dlx-2, and Dlx-1 and -2 alter morphogenesis of proximal skeletal and soft tissue structures derived from the first and second arches. *Dev Biol* **185**: 165–184.
- Satokata, I., Ma, L., Ohshima, H., Bei, M., Woo, I., Nishizawa, K., Maeda, T., Takano, Y., Uchiyama, M., Heaney, S., et al. 2000. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. *Nat Genet* **24**: 391–395.
- Scherer, S.W., Poorkaj, P., Massa, H., Soder, S., Allen, T., Nunes, M., Geshuri, D., Wong, E., Belloni, E., and Little, S. 1994. Physical mapping of the split hand/split foot locus on chromosome 7 and implication in syndromic ectrodactyly. *Hum Mol Gen* **3**: 1345–1354.
- Seto, M.L., Nunes, M.E., MacArthur, C.A., and Cunningham, M.L. 1997. Pathogenesis of ectrodactyly in the Dactylaplasia mouse: aberrant cell death of the apical ectodermal ridge. *Teratology* **56**: 262–270.
- Sheehan, D.C. and Hrapchak, B.B. 1987. *Theory and practice of histotechnology*. Battelle Press, Columbus, OH.
- Shirakabe, K., Terasawa, K., Miyama, K., Shibuya, H., and Nishida, E. 2001. Regulation of the activity of the transcription factor Runx2 by two homeobox proteins, Msx2 and Dlx5. *Genes Cells* **6**: 851–856.
- Simeone, A., Acampora, D., Pannese, M., D'Esposito, M., Stornaiuolo, A., Gulisano, M., Mallamaci, A., Kastury, K., Druck, T., and Huebner, K. 1994. Cloning and characterization of two members of the vertebrate Dlx gene family. *Proc Natl Acad Sci* **91**: 2250–2254.
- Smits, P., Li, P., Mandel, J., Zhang, Z., Deng, J.M., Behringer, R.R., de Crombrughe, B., and Lefebvre, V. 2001. The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. *Dev Cell* **1**: 277–290.
- Tackels-Horne, D., Toburen, A., Sangiorgi, E., Gurrieri, F., de Mollerat, X., Fischetto, R., Causio, F., Clarkson, K., Stevenson, R.E., and Schwartz, C.E. 2001. Split hand/split foot malformation with hearing loss: First report of families linked to the SHFM1 locus in 7q21. *Clin Genet* **59**: 28–36.
- Takeda, S., Bonnamy, J.P., Owen, M.J., Ducy, P., and Karsenty, G. 2001. Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. *Genes Dev* **15**: 467–481.
- Temtamy, S.A. and McKusick, V.A. 1978. The genetics of hand malformations. *Birth Defects Orig Artic Ser* **14**: 1–619.
- ten Berge, D., Brouwer, A., el Bahi, S., Guenet, J.L., Robert, B., and Meijlink, F. 1998. Mouse Alx3: An aristaless-like homeobox gene expressed during embryogenesis in ectomesenchyme and lateral plate mesoderm. *Dev Biol* **199**: 11–25.
- Thomas, T., Kurihara, H., Yamagishi, H., Kurihara, Y., Yazaki, Y., Olson, E.N., and Srivastava, D. 1998. A signaling cascade involving endothelin-1, dHAND and msx1 regulates development of neural-crest-derived branchial arch mesenchyme. *Development* **125**: 3005–3014.
- Tribioli, C. and Lufkin, T. 1999. The murine Bapx1 homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. *Development* **126**: 5699–5711.
- Wang, W., Chan, E.K., Baron, S., Van de Water, T., and Lufkin, T. 2001. Hmx2 homeobox gene control of murine vestibular morphogenesis. *Development* **128**: 5017–5029.
- Wang, W., Lo, P., Frasch, M., and Lufkin, T. 2000. Hmx: An evolutionary conserved homeobox gene family expressed in the developing nervous system in mice and Drosophila. *Mech Dev* **99**: 123–137.
- Zelzer, E., Glotzer, D.J., Hartmann, C., Thomas, D., Fukai, N., Soker, S., and Olsen, B.R. 2001. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. *Mech Dev* **106**: 97–106.
- Zerucha, T., Stuhmer, T., Hatch, G., Park, B.K., Long, Q., Yu, G., Gambarotta, A., Schultz, J.R., Rubenstein, J.L., and Ecker, M. 2000. A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. *J Neurosci* **20**: 709–721.

The *Dlx5* and *Dlx6* homeobox genes are essential for craniofacial, axial, and appendicular skeletal development

Raymond F. Robledo, Lakshmi Rajan, Xue Li, et al.

Genes Dev. 2002, **16**:

Access the most recent version at doi:[10.1101/gad.988402](https://doi.org/10.1101/gad.988402)

References

This article cites 46 articles, 11 of which can be accessed free at:
<http://genesdev.cshlp.org/content/16/9/1089.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).